TREK-1 K + channels in the cardiovascular system: Their significance and potential as a therapeutic target

Cardiovascular Therapeutics

Volumn 30, Issue 1, 2012, Pages

  Goonetilleke, Lakshman ^a   Quayle, John ^b  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

Arrhythmia; Artery; K + channel; Neuroprotection; TREK 1; Two pore domain; Vasodilator

Indexed keywords

AMIDE; AMINOPYRIDINE; CARDIOVASCULAR AGENT; CHLOROFORM; DOCOSAHEXANOIC ACID; ESSENTIAL FATTY ACID; FLUOXETINE; HALOTHANE; ICOSAPENTAENOIC ACID; INHALATION ANESTHETIC AGENT; ISOFLURANE; LINOLEIC ACID; LINOLENIC ACID; LOCAL ANESTHETIC AGENT; NEUROPROTECTIVE AGENT; NITRIC OXIDE; NITROUS OXIDE; NORFLUOXETINE; OMEGA 3 FATTY ACID; POLYUNSATURATED FATTY ACID; POTASSIUM CHANNEL BLOCKING AGENT; POTASSIUM CHANNEL STIMULATING AGENT; RILUZOLE; SEROTONIN UPTAKE INHIBITOR; SIPATRIGINE; TREK 1 POTASSIUM CHANNEL; UNCLASSIFIED DRUG; VOLTAGE GATED POTASSIUM CHANNEL; XENON;

AMYOTROPHIC LATERAL SCLEROSIS; BLOOD VESSEL; BLOOD VESSEL REACTIVITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR EFFECT; CARDIOVASCULAR SYSTEM; CELL MEMBRANE PERMEABILITY; CELL PH; DRUG SAFETY; DRUG TARGETING; ENZYME ACTIVITY; EXCITATION CONTRACTION COUPLING; EXPERIMENTAL MOUSE; EXPERIMENTAL RAT; EXTRACELLULAR MATRIX; HEART ARRHYTHMIA; HEART DEATH; HEART INFARCTION; HEART MUSCLE CELL; HEART PROTECTION; HUMAN; HYPERTENSION; INTRACELLULAR MEMBRANE; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN FAMILY; PROTEIN FUNCTION; REGULATORY MECHANISM; REVIEW; SECOND MESSENGER; TEMPERATURE; VASCULAR SMOOTH MUSCLE; VASODILATATION;

ANIMALS; BLOOD VESSELS; CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; HEART; HUMANS; ION CHANNEL GATING; MYOCARDIUM; PERMEABILITY; POTASSIUM CHANNELS, TANDEM PORE DOMAIN;

EID: 84856257200     PISSN: 17555914     EISSN: 17555922     Source Type: Journal    
DOI: 10.1111/j.1755-5922.2010.00227.x     Document Type: Review

References (70)

1. Snyders DJ. Structure and function of cardiac potassium channels. Cardiovasc Res 1999;42:377-390.
2. Nelson MT, Quayle JM. Physiological roles and properties of potassium channels in arterial smooth muscle. Am J Physiol 1995;268:C799-C822.
3. Coghlan MJ, Carroll WA, Gopalakrishnan M. Recent developments in the biology and medicinal chemistry of potassium channel modulators: Update from a decade of progress. J Med Chem 2001;44:1627-1653.
4. Judge SI, Smith PJ. Patents related to therapeutic activation of K(ATP) and K(2P) potassium channels for neuroprotection: Ischemic/hypoxic/anoxic injury and general anesthetics. Expert Opin Ther Pat 2009;19:433-460.
5. Hibino H, Inanobe A, Furutani K, Murakami S, Findlay I, Kurachi Y. Inwardly rectifying potassium channels: Their structure, function, and physiological roles. Physiol Rev 2010;90:291-366.
6. + channels. Trends Neurosci 2001;24:339-346.
7. Backx PH, Marban E. Background potassium current active during the plateau of the action-potential in guinea-pig ventricular myocytes. Circ Res 1993;72:890-900.
8. Kim D, Clapham DE. Potassium channels in cardiac-cells activated by arachidonic-acid and phospholipids. Science 1989;244:1174-1176.
9. Yue DT, Marban E. A novel cardiac potassium channel that is active and conductive at depolarized potentials. Pflugers Arch 1988;413:127-133.
10. + currents in single smooth-muscle cells of the rabbit portal-vein. J Physiol 1989;413:49-73.
11. + channels in the control of membrane potential in rabbit renal arcuate artery. J Physiol 1998;511:159-169.
12. Wilde DW, Lee KS. Outward potassium currents in freshly isolated smooth-muscle cell of dog coronary-arteries. Circ Res 1989;65:1718-1734.
13. Goldstein SAN, Bayliss DA, Kim D, Lesage F, Plant LD, Rajan S. International Union of Pharmacology. LV. Nomenclature and molecular relationships of two-P potassium channels. Pharmacol Rev 2005;57:527-540.
14. Gurney A, Manoury B. Two-pore potassium channels in the cardiovascular system. Eur Biophys J 2009;38:305-318.
15. Bayliss DA, Barrett PQ. Emerging roles for two-pore-domain potassium channels and their potential therapeutic impact. Trends Pharmacol Sci 2008;29:566-575.
16. 2P channels: Chemo- and nutrient sensors. Trends Neurosci 2007;30:573-580.
17. 2P channels: Focus on TREK1. Nature Rev Neurosci 2007;8:251-261.
18. + channels. Trends Pharmacol Sci 2003;24:648-654.
19. Sabbadini M, Yost CS. Molecular biology of background K channels: Insights from K-2P knockout mice. J Mol Biol 2009;385:1331-1344.
20. + channel. EMBO J 1998;17:4283-4290.
21. 2P channel TREK-1. Eur Biophys J 2009;38:293-303.
22. + channel. Biochem Biophys Res Commun 2002;292:339-346.
23. Bockenhauer D, Zilberberg N, Goldstein SAN. KCNK2: Reversible conversion of a hippocampal potassium leak into a voltage-dependent channel. Nature Neurosci 2001;4:486-491.
24. Maingret F, Patel AJ, Lesage F, Lazdunski M, Honoré E. Mechano- or acid stimulation, two interactive modes of activation of the TREK-1 potassium channel. J Biol Chem 1999;274:26691-26696.
25. Honoré E, Patel AJ, Chemin J, Suchyna T, Sachs F. Desensitization of mechano-gated K-2P channels. PNAS 2006;103:6859-6864.
26. + channel. EMBO J 2000;19:2483-2491.
27. + channels TREK-1 and TRAAK. J Biol Chem 2000;275:10128-10133.
28. + channels. J Biol Chem 2005;280:4415-4421.
29. + channel TREK-1. EMBO J 2005;24:44-53.
30. + channels. J Physiol 2005;564:117-129.
31. + channel TREK-1. EMBO J 2002;21:2968-2976.
32. Murbartian J, Lei Q, Sando JJ, Bayliss D. Sequential phosphorylation mediates receptor- and kinase-induced inhibition of TREK-1 background potassium channels. J Biol Chem 2005;280:30175-30184.
33. + channels. EMBO J 2003;22:5403-5411.
34. Koh SD, Monaghan K, Sergeant GP, Ro S, Walker RL, Sanders KM, Horowitz B. TREK-1 regulation by nitric oxide and cGMP-dependent protein kinase. An essential role in smooth muscle inhibitory neurotransmission. J Biol Chem 2001;276:44338-44346.
35. + channels. Nat Neurosci 1999;2:422-426.
36. + channel involved in neuroprotection and general anesthesia. EMBO J 2004;23:2684-2695.
37. + channel subunits: Kinetic properties and expression in rat heart. Am J Physiol 1999;277:H1669-H1678.
38. + channel genes in adult and embryonic rat heart quantified by real-time polymerase chain reaction. Clin Exp Pharmacol Physiol 2004;31:174-178.
39. Lopes CMB, Gallagher PG, Buck ME, Butler MH, Goldstein SAN. Proton block and voltage gating are potassium-dependent in the cardiac leak channel Kcnk3. J Biol Chem 2000;275:16969-16978.
40. Putzke C, Wemhoner K, Sachse FB, et al. The acid-sensitive potassium channel TASK-1 in rat cardiac muscle. Cardiovasc Res 2007;75:59-68.
41. Terrenoire C, Lauritzen I, Lesage F, Romey G, Lazdunski M. A TREK-1-like potassium channel in atrial cells inhibited by beta-adrenergic stimulation and activated by volatile anesthetics. Circ Res 2001;89:336-342.
42. Ruskoaho H. Atrial-natriuretic-peptide: Synthesis, release, and metabolism. Pharmacol Rev 1992;44:479-602.
43. Kelly D, Mackenzie L, Hunter P, Smaill B, Saint DA. Gene expression of stretch-activated channels and mechanoelectric feedback in the heart. Clin Exp Pharmacol Physiol 2006;33:642-648.
44. Li XT, Dyachenko V, Zuzarte M, Putzke C, Preisig-Muller R, Isenberg G, Daut J. The stretch-activated potassium channel TREK-1 in rat cardiac ventricular muscle. Cardiovasc Res 2006;69:86-97.
45. Tan JHC, Liu WH, Saint DA. Differential expression of the mechanosensitive potassium channel TREK-1 in epicardial and endocardial myocytes in rat ventricle. Exp Physiol 2004;89:237-242.
46. Kohl P, Ravens U. Cardiac mechano-electric feedback: Past, present, and prospect. Prog Biophys Mol Biol 2003;82:3-9.
47. TREK in cardiomyocytes. J Biol Chem 2000;275:39110-39116.
48. Sandoz G, Douguet D, Chatelain F, Lazdunski M, Lesage F. Extracellular acidification exerts opposite actions on TREK1 and TREK2 potassium channels via a single conserved histidine residue. PNAS 2009;106:14628-14633.
49. Gardener MJ, Johnson IT, Burnham MP, Edwards G, Heagerty AM, Weston AH. Functional evidence of a role for two-pore domain potassium channels in rat mesenteric and pulmonary arteries. Br J Pharmacol 2004;142:192-202.
50. Goonetilleke L. Two-pore domain potassium channels in arterial smooth muscle. Ph.D. thesis. University of Liverpool, Liverpool, UK, 2007.
51. + channel, TASK-1, in pulmonary artery smooth muscle cells. Circ Res 2003;93:957-964.
52. Bryan RM, You JP, Phillips SC, et al. Evidence for two-pore domain potassium channels in rat cerebral arteries. Am J Physiol 2006;291:H770-H780.
53. + channels in normal and impaired EDHF-dilator responses-relevance to cardiovascular pathologies and drug discovery. Br J Pharmacol 2009;157:509-526.
54. Garry A, Fromy B, Blondeau N, et al. Altered acetylcholine, bradykinin and cutaneous pressure-induced vasodilation in mice lacking the TREK1 potassium channel: The endothelial link. EMBO Rep 2007;8:354-359.
55. Dyall SC, Michael-Titus AT. Neurological benefits of omega-3 fatty acids. Neuromolecular Med 2008;10:219-235.
56. Jung UJ, Torrejon C, Tighe AP, Deckelbaum R. n-3 Fatty acids and cardiovascular disease: Mechanisms underlying beneficial effects. Am J Clin Nutrition 2008;87:2003s-2009s.
57. Lauritzen I, Blondeau N, Heurteaux C, Widmann C, Romey G, Lazdunski M. Polyunsaturated fatty acids are potent neuroprotectors. EMBO J 2000;19:1784-1793.
58. Blondeau N, Petrault O, Manta S, et al. Polyunsaturated fatty acids are cerebral vasodilators via the TREK-1 potassium channel. Circ Res 2007;101:176-184.
59. Mathie A, Veale EL. Therapeutic potential of neuronal two pore domain potassium channel modulators. Curr Opin Investig Drugs 2007;8:555-562.
60. + channels TREK-1 and TRAAK. Brain Res 2001;892:94-101.
61. Kennard LE, Chumbley JR, Ranatunga KM, Armstrong SJ, Veale EL, Mathie A. Inhibition of the human two-pore domain potassium channel, TREK-1, by fluoxetine and its metabolite norfluoxetine. Br J Pharmacol 2005;144:821-829.
62. Heurteaux C, Lucas G, Guy N, et al. Deletion of the background potassium channel TREK-1 results in a depression-resistant phenotype. Nature Neurosci 2006;9:1134-1141.
63. Kindler CH, Yost CS, Gray AT. Local anaesthetic inhibition of baseline potassium channels with two pore domains in tandem. Anaesthesiology 1999;90:1092-1102.
64. Kindler CH, Yost CS. Two pore domain potassium channels: New sites of local anaesthetic action and toxicity. Reg Anesth Pain Med 2005;30:260-274.
65. + channels are a novel target for the anaesthtic gases xenon, nitrous oxide, and cyclopropane. Mol Pharmacol 2004;65:443-452.
66. Landoni G, Fochi O, Torri G. Cardiac protection by volatile anaesthetics: A review. Curr Vasc Pharmacol 2008;6:108-111.
67. + channels TREK-1 and TRAAK. Mol Pharmacol 2000;57:906-912.
68. Pokojski S, Busch C, Grgic I, et al. TWIK-related two-pore domain potassium channel TREK-1 in carotid endothelium of normotensive and hypertensive mice. Cardiovasc Res 2008;79:80-88.
69. Pokojski S, Busch C, Grgic I, et al. TWIK-related two-pore domain potassium channel TREK-1 in carotid endothelium of normotensive and hypertensive mice. Cardiovasc Res 2008;80:320-320. (Retraction).
70. + channels in cerebrovascular smooth muscle. Am J Physiol 2009;296:H1774-H1780.